The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors
Open accessAbstract
Purpose: To assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of E7107 administered as 5-minute bolus infusions on days 1, 8, and 15 in a 28-day schedule. Experimental Design: Patients with solid tumors refractory to standard therapies or with no standard treatment available were enrolled. Dose levels of 0.6 to 4.5 mg/m2 were explored. Results: Forty patients [24M/16F, median age 61 years (45–79)] were enrolled. At 4.5 mg/m2, dose-limiting toxicity (DLT) consisted of grade 3 diarrhea, nausea, and vomiting and grade 4 diarrhea, respectively, in two patients. At 4.0 mg/m2, DLT (grade 3 nausea, vomiting, and abdominal cramps) was observed in one patient. Frequently occurring side effects were mainly gastrointestinal. After drug discontinuation at 4.0 mg/m2, one patient experienced reversible grade 4 blurred vision. The maximum tolerated dose (MTD) is 4.0 mg/m2. No complete or partial responses during treatment were observed; one patient at 4.0 mg/m2 had a confirmed partial response after drug discontinuation. Pharmacokinetic analysis revealed a large volume of distribution, high systemic clearance, and a plasma elimination half-life of 5.3 to 15.1 hours. Overall drug exposure increased in a dose-dependent manner. At the MTD, mRNA levels of selected target genes monitored in peripheral blood mononuclear cells showed a reversible 15- to 25-fold decrease, whereas unspliced pre-mRNA levels of DNAJB1 and EIF4A1 showed a reversible 10- to 25-fold increase. Conclusion: The MTD for E7107 using this schedule is 4.0 mg/m2. Pharmacokinetics is dose-dependent and reproducible within patients. Pharmacodynamic analysis revealed dose-dependent reversible inhibition of pre-mRNA processing of target genes, confirming proof-of-principle activity of E7107. Clin Cancer Res; 19(22); 6296–304. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J. S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103283 · Cited by 1,222
SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
Wang, L., Lawrence, M. S., Wan, Y., Stojanov, P., Sougnez, C., Stevenson, K., Werner, L., Sivachenko, A., DeLuca, D. S., Zhang, L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1109016 · Cited by 1,080
Splicing factor SF3b as a target of the antitumor natural product pladienolide
Kotake, Y., Sagane, K., Owa, T., Mimori-Kiyosue, Y., Shimizu, H., Uesugi, M., Ishihama, Y., Iwata, M., & Mizui, Y. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.16 · Cited by 657
Self-citationSpliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA
Kaida, D., Motoyoshi, H., Tashiro, E., Nojima, T., Hagiwara, M., Ishigami, K., Watanabe, H., Kitahara, T., Yoshida, T., Nakajima, H., et al. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.18 · Cited by 650
Burger, H., Foekens, J. A., Look, M. P., Gelder, M. E. M., Klijn, J. G. M., Wiemer, E. A. C., Stoter, G., & Nooter, K. (2003) · PubMed · Cited by 292
Self-citationSF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts
Visconte, V, Makishima, H., Jankowska, A., Szpurka, H., Traina, F., Jerez, A., O'Keefe, C., Rogers, H. J., Sekeres, M. A., Maciejewski, J. P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.232 · Cited by 213
Patnaik, M. M., Lasho, T. L., Hodnefield, J. M., Knudson, R. A., Ketterling, R. P., Garcia-Manero, G., Steensma, D. P., Pardanani, A., Hanson, C. A., & Tefferi, A. (2012) · Blood · doi:10.1182/blood-2011-09-377994 · Cited by 202
The Biflavonoid Isoginkgetin Is a General Inhibitor of Pre-mRNA Splicing
O'Brien, K., Matlin, A. J., Lowell, A. M., & Moore, M. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805556200 · Cited by 200
MIZUI, Y., SAKAI, T., IWATA, M., UENAKA, T., OKAMOTO, K., SHIMIZU, H., YAMORI, T., YOSHIMATSU, K., & ASADA, M. (2004) · The Journal of Antibiotics · doi:10.7164/antibiotics.57.188 · Cited by 185
Self-citation
Cited by
Goodall, G. J., & Wickramasinghe, V. O. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00306-0 · Cited by 1,066
Roles and mechanisms of alternative splicing in cancer — implications for care
Bonnal, S. C., López-Oreja, I., & Valcárcel, J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0350-x · Cited by 731
RNA splicing factors as oncoproteins and tumour suppressors
Dvinge, H., Kim, E., Abdel-Wahab, O., & Bradley, R. K. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.51 · Cited by 687
RNA splicing dysregulation and the hallmarks of cancer
Bradley, R. K., & Anczuków, O. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00541-7 · Cited by 579
Therapeutic targeting of splicing in cancer
Lee, S. C.-W., & Abdel-Wahab, O. (2016) · Nature Medicine · doi:10.1038/nm.4165 · Cited by 561
Metadata
- Authors
- Eskens, F. A. L. M., Ramos, F. J., Burger, H., O'Brien, J. P., Piera, A., de Jonge, M. J. A., Mizui, Y., Wiemer, E. A. C., Carreras, M. J., Baselga, J., & Tabernero, J.
- Venue
- Clinical Cancer Research
- Published
- 2013-11-14
- Volume
- 19
- Issue
- 22
- Pages
- 6296-6304
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2160078712
- Cited by
- 259
- References
- 15
- FWCI
- 4.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-13-0485
- The paper
- Eskens, F. A. L. M., Ramos, F. J., Burger, H., O'Brien, J. P., Piera, A., de Jonge, M. J. A., Mizui, Y., Wiemer, E. A. C., Carreras, M. J., Baselga, J., & Tabernero, J. (2013). Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-13-0485
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.